Related Experiment Videos
[Post-therapy surveillance in non-Hodgkin's lymphomas]
Cécile Fohrer1, Corina Oprea, Raoul Herbrecht
1Département d'hématologie et d'oncologie Hôpital de Hautepierre, 67098 Strasbourg.
La Revue Du Praticien
|June 18, 2002
Summary
Regular surveillance after non-Hodgkin's lymphoma treatment is crucial for detecting relapses and late complications. Monitoring frequency depends on lymphoma type, balancing early detection with patient well-being.
Area of Science:
- Oncology
- Hematology
- Clinical Medicine
Context:
- Post-treatment surveillance is essential for non-Hodgkin's lymphoma (NHL) patients.
- Relapse risk varies significantly between aggressive and low-grade NHL subtypes.
- Late treatment-related complications, including secondary cancers and organ toxicities, necessitate ongoing monitoring.
Purpose:
- To outline the necessity and components of post-treatment surveillance in non-Hodgkin's lymphoma.
- To differentiate surveillance strategies based on lymphoma subtype and relapse risk.
- To highlight the importance of monitoring for late chemotherapy-induced toxicities.
Summary:
- Surveillance for non-Hodgkin's lymphoma involves clinical exams and biological tests (CBC, LDH, beta-2-microglobulin), with imaging based on initial presentation.
- Aggressive lymphomas have a higher early relapse risk, while low-grade lymphomas present a more prolonged and constant relapse risk.
- Late complications like secondary malignancies (solid tumors, leukemia) and organ damage (cardiac, endocrine) require vigilant clinical and biological follow-up.
Impact:
- Informs clinical practice guidelines for optimal non-Hodgkin's lymphoma patient follow-up.
- Aids in the timely diagnosis of lymphoma relapse, improving patient outcomes.
- Facilitates early detection and management of treatment-related toxicities, enhancing long-term patient quality of life.